EphB2 is a receptor tyrosine kinase of the Eph family and ephrin-B1 is one of its transmembrane ligands. In the embryo, EphB2 and ephrin-B1 participate in neuronal axon guidance, neural crest cell migration, the formation of blood vessels, and the development of facial structures and the inner ear. Interestingly, EphB2 and ephrin-B1 can both signal through their cytoplasmic domains and become tyrosine-phosphorylated when bound to each other. Tyrosine phosphorylation regulates EphB2 signaling and likely also ephrin-B1 signaling. Embryonic retina is a tissue that highly expresses both ephrin-B1 and EphB2. Although the expression patterns of EphB2 and ephrin-B1 in the retina are different, they partially overlap, and both proteins are substantially tyrosine-phosphorylated. To understand the role of ephrin-B1 phosphorylation, we have identified three tyrosines of ephrin-B1 as in vivo phosphorylation sites in transfected 293 cells stimulated with soluble EphB2 by using mass spectrometry and site-directed mutagenesis. These tyrosines are also physiologically phosphorylated in the embryonic retina, although the extent of phosphorylation at each site may differ. 
required to restrict intermingling between populations of Eph receptor-bearing cells and B-ephrin-bearing cells (7) . This implies that activation of ephrin-B signaling drives cell sorting in the developing hindbrain, similar to activation of Eph receptor signaling (8) . Furthermore, ectopic overexpression of ephrin-B1 in Xenopus embryos causes cell dissociation (9, 10) , an effect that requires the 19 carboxyl-terminal amino acids of the ephrin-B1 cytoplasmic domain (9) . The cytoplasmic domain of ephrin-B1 is also required to inhibit oncogenic signaling pathways activated by tyrosine kinases (11, 12) .
Knock out studies in the mouse support the idea that signals mediated by ephrin-B1 and ephrin-B3 control axon pathfinding in the embryonic brain anterior commissure and the developing retina (13, 14) , whereas signals mediated by ephrin-B2 control the formation of the vascular system (15, 16) .
Consistent with the ephrin-B ligands having receptor-like intrinsic signaling properties, a soluble form of the EphB4 receptor ectodomain induces angiogenic sprouting of endothelial cells in vitro, presumably by "activating' signaling through the ephrin-B2 ligand expressed in these cells (16) . In addition, in in vitro experiments the EphB2 ectodomain inhibits chemoattraction of cerebellar granule cells to the SDF-1 chemokine, presumably by activating signaling through the ephrin-B1 ligand expressed in these cells (17) .
Interestingly, treatment of cultured cells expressing ephrin-B ligands with soluble EphB receptor ectodomains induces tyrosine phosphorylation of the B-ephrins (12, 18) . The cytoplasmic domains of the three B-ephrins consist of ϳ80 amino acids, including five conserved tyrosine residues. Ephrin-B1, in addition, contains a sixth cytoplasmic tyrosine. Tyrosine phosphorylation likely plays an important role in ephrin-B signaling, but the specific tyrosines involved have remained elusive. Here we identify tyrosine phosphorylation sites in the cytoplasmic domain of ephrin-B1 from 293 cells stimulated with a soluble form of the EphB2 ectodomain. Importantly, these ephrin-B1 phosphorylation sites were also detected in the embryonic neural retina, indicating that the in vivo phosphorylation sites in retinal tissue are the same as in cultured cells. In addition, we identify phosphorylated tyrosines of EphB2 from embryonic retinal tissue that confirm that phosphorylation sites previously identified in 293 cells (19) have physiological significance in vivo. These phosphorylated tyrosines likely regulate EphB2 kinase activity and interactions with signaling proteins in response to ligand binding. Thus, ephrin-B ligands and EphB receptors form bidirectional signaling complexes in which both the receptor and the ligand become tyrosine-phosphorylated in their cytoplasmic domains and have increased signaling capacity. An important step in the characterization of ephrin-B-EphB bidirectional signaling is to identify the tyrosines that become phosphorylated in the complex under physiological conditions. The approaches that we have used can be generally applied to the determination of protein-tyrosine phosphorylation sites in animal tissues.
EXPERIMENTAL PROCEDURES
Materials-Protease inhibitors, anti-phosphotyrosine antibodies coupled to agarose (clone PT-66), and protein A-peroxidase were obtained from Sigma. Endoproteinases used in mapping phosphorylated tyrosines by mass spectrometry were of sequencing grade from Promega or Roche Molecular Biochemicals. 1-O-Octyl-␤-D-glucopyranoside and ␣-cyano-4-hydroxcinnamic acid were obtained from Aldrich. Chemicals used for mass spectrometry experiments were of high pressure liquid chromatography grade or the best grade available. The Voyager MALDI-TOF 1 mass spectrometer was from PerSeptive Biosystems. Electrospray mass spectra were recorded on a PerkinElmer Sciex API 3000 triple quadrupole mass spectrometer from Applied Biosystems that was fitted with a nano-electrospray source and capillaries from Protana. The enhanced chemiluminescence system and GammaBind Plus Sepharose were from Amersham Pharmacia Biotech. Zip tips packed with C 18 were from Millipore Corporation. EphB2 Fc was prepared as previously described (20) .
Plasmids-The pcDNA3-EphB2 and pcDNA3-ephrin-B1 Fc plasmids have been previously described (20, 22) . The pcDNA3-ephrin-B1 plasmid contains the coding sequence of chicken ephrin-B1, which was amplified with the sense primer GTCCATGGCGCGGCCCCGCGGCG-GGCGGTGGC (containing an NcoI site, underlined) and the antisense primer CGGAATTCACACCTTGTAGTAAATGTTGGCTG (containing an EcoRI site, underlined) and cloned into the NcoI and EcoRI sites of the pCla12NcoI adaptor plasmid (21) . The sequence was then digested from pCla12NcoI with XbaI and cloned into pcDNA3, and a clone in the appropriate orientation was selected by restriction digestion.
Ephrin-B1 Site-directed Mutagenesis-To mutate tyrosines in the cytoplasmic domain of ephrin-B1 to phenylalanine, site-directed mutagenesis was performed by sequential PCR steps using pcDNA3-ephrin-B1 as template and overlapping primers encoding the mutations. Pfu DNA polymerase (Stratagene) was used for PCR amplification. For mutations of tyrosine 301 or 305, two overlapping fragments were produced by PCR amplification. The 5Ј fragment was obtained by amplification of wild type ephrin-B1 with the T7 sense primer and the ephrin-B1 antisense primer ACCTTCTCGAAGTGCGGGCAGTAG (the mutated nucleotide that changes tyrosine 305 to phenylalanine is underlined). The 3Ј fragment was obtained by amplification with the ephrin-B1 sense primer GAGAA-CAACTTCTGCCCGCACTAC (the mutated nucleotide that changes tyrosine 301 to phenylalanine is underlined) and the SP6 antisense primer. PCR amplification of a mixture of the two overlapping fragments with T7 and SP6 primers yielded a mixture of cDNAs mutated at either tyrosine 301 or tyrosine 305, which were digested with EcoRV and ApaI, cloned into similarly digested pcDNA3, and sequenced to confirm the desired constructs. For mutation of tyrosine 312 or 317, the same approach was used with the antisense ephrin-B1 primer TGCACGATGAAGACGGGGT-GCCC (the mutated nucleotide that changes tyrosine 317 to phenylalanine is underlined) and the sense ephrin-B1 primer GCGGGGACT-TCGGGCACCCCGTC (the mutated nucleotide that changes tyrosine 312 to phenylalanine is underlined). To obtain the tyrosine 331 ephrin-B1 mutant (Y331F) and the double mutants Y312F/Y331F and Y317F/ Y331F, a single amplification was performed with the T7 sense primer and the antisense ephrin-B1 primer TCACACCTTGTAGAAAATGTT-GGC (the mutated nucleotide that changes tyrosine 331 to phenylalanine is underlined). The templates were wild type ephrin-B1 (to obtain Y331F), ephrin-B1 Y312F (to obtain Y312F/Y331F), or ephrinB1 Y317F (to obtain Y317F/Y331F). The amplified fragments were digested with EcoRI and cloned into EcoRI-and SmaI-digested pcDNA3. Finally, the triple ephrin-B1 mutant Y312F/Y317F/Y331F was obtained by (a) amplifying the ephrin-B1 Y312F cDNA with the T7 sense primer and the reverse primer containing the 317 mutation; (b) amplifying the ephrin-B1 Y317F cDNA with the sense primer containing the 312 mutation and the reverse primer containing the Y331F mutation; and (c) amplifying the mixture of the two fragments amplified in steps a and b with the T7 primer and the antisense primer containing the 331 mutation.
Antibodies-Anti-EphB2 antibodies were to a glutathione S-transferase fusion protein comprising ϳ100 amino acids of the EphB2 carboxyl terminus and have been described (20) . Anti-ephrin-B1 antibodies were prepared using a chicken ephrin-B1 Fc fusion protein as the antigen and for affinity purification. The affinity-purified antibodies were then absorbed on a human Fc column (ICN/Cappel) to eliminate antibodies to the Fc portion of the protein. The antibodies are specific for chicken ephrin-B1 and do not appear to cross-react with mouse ephrin-B1 and other B-ephrins. Anti-phosphotyrosine antibodies conjugated to horseradish peroxidase were from Transduction Laboratories.
Cell Culture and Transfections-The 293T human embryonal kidney cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 g of streptomycin, and 1 mM sodium pyruvate. Transient transfections for mass spectrometry experiments were performed by the calcium phosphate method as previously described (22) , using 10 g of plasmid DNA/10-cm dish. Transient transfections with the ephrin-B1 tyrosine to phenylalanine mutants were performed using the SuperFect transfection reagent (Qiagen) and 2.5 g of plasmid DNA/6-cm dish. For stimulation of ephrin-B1, the cells were serum starved overnight and stimulated for 20 min with 2 g/ml EphB2 Fc that had been crosslinked by preincubation with 0.2 g/ml anti-Fc antibodies (ICN/Cappel) for 30 min on ice.
Immunoprecipitation and Immunoblotting-For the experiment shown in Fig. 1A , ephrin-B1 was immunoprecipitated from 293T cells lysed in Brij buffer using 10 g of anti-ephrin-B1 antibodies bound to 10 l of protein G beads. For the experiments shown in Fig. 3 , 5 g of anti-ephrin-B1 antibodies were used bound to 10 l of protein G beads. Retina extracts were prepared by sonicating retinal tissue in RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholic acid with sodium, 0.1% SDS, 50 mM Tris, pH 8.0, 1 mM sodium pervanadate, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml protease inhibitors). Immunoprecipitated from retinal tissue were with 5 g of antiephrin-B1 antibodies and 2 g of anti-EphB2 antibodies. The samples were separated by SDS-polyacrylamide gel electrophoresis, electrotransferred to polyvinylidene difluoride membranes (Millipore), and stained with Amido Black. The filters were then incubated for 1-2 h in 3% bovine serum albumin in TBS and incubated with primary antibodies for 1-2 h in 3% bovine serum albumin, 0.1% polyoxyethylenesorbitan monolaurate (Tween 20) in TBS (see Fig. 1A ) or in 0.05% Tween 20 in TBS (see Figs. 4 and 5). Affinity-purified anti-ephrin-B1 and anti-EphB2 antibodies were used at 1 or 0.5 g/ml, respectively, followed by protein A-peroxidase (1:10,000 dilution) for 1 h. Tyrosine phosphorylation was detected with anti-phosphotyrosine antibodies conjugated to horseradish peroxidase (1:10,000 dilution). An enhanced chemiluminescence system was used for detection. Reprobing was performed after stripping bound antibodies with 1 h of incubation in 2% SDS, 100 mM mercaptoethanol, 62.5 mM Tris, pH 7.5.
MALDI-TOF Mass Spectrometry-E12 chicken retinas or 293T cells transiently transfected with ephrin-B1 or EphB2 were lysed in 1% Triton X-100 in TBS containing protease inhibitors and 5 mM EDTA. Before lysis, the ephrin-B1 transfected 293T cells were treated for 20 min with 2.5 g/ml EphB2 Fc that had been preincubated for 30 min at 4°C with 0.25 g/ml anti-human Fc antibody (Cappel). The lysates were incubated with 100 g of anti-ephrin-B1 or anti-EphB2 antibodies bound to 30 l of GammaBind plus Sepharose for 2 h at 4°C. The samples were washed three times in Triton X-100 in TBS containing 1 mM sodium orthovanadate and 10 mM NaF, and three times in 0.1% 1-O-octyl-␤-D-glucopyranoside (98%), 100 mM NH 4 HCO 3 , pH 7.5, containing 1 mM sodium orthovanadate. Endoproteinase Glu-C/trypsin proteolytic digestions were performed with sequence grade proteases in 100 l of 100 mM NH 4 HCO 3 , pH 8.0, at 37°C overnight with endoproteinase Glu-C (50 ng/l) first, followed by a overnight tryptic digestion at 37°C (50 ng/l). Endoproteinases were inhibited with phenylmethylsulfonyl fluoride (100 g/ml). The digested samples were centrifuged, and the supernatants were removed. The sedimented beads were washed twice with 200 l of 100 mM NH 4 HCO 3 , pH 8.0, containing phenylmethylsulfonyl fluoride, and the supernatant and wash were combined with 20 l of anti-phosphotyrosine antibodies conjugated to agarose (23) for overnight incubation at 4°C. The beads were washed four times with 100 mM NH 4 HCO 3 , pH 8.0, and then packed into a 10-l Geloader Tip (Eppendorf). The beads in the tip were washed three times with 60 l of 100 mM NH 4 HCO 3 , pH 8.0. The phosphopeptides were eluted in 20-l aliquots of 100 mM phosphate, pH 2.5, directly into a zip tip packed with C 18 , which had been equilibrated by washing three times with 20 l of 75% acetonitrile, 0.1% trifluoroacetic acid followed by three times with 20 l of 0.1% trifluoroacetic acid. After cycling each acid eluate through the zip tip five times, the tip was washed five times with 20 l of 0.1% trifluoroacetic acid. For samples submitted for MALDI analysis, the phosphopeptides were eluted from the zip tip in 3 l of 10 mg/ml ␣-cyano-4-hydroxcinnamic acid in 3 l of 75% acetonitrile, 0.1% trifluoroacetic acid directly onto a target.
Mass spectra were collected on a Voyager MALDI-TOF mass spec-trometer equipped with a nitrogen laser, delayed extraction, and a reflector. Spectra were externally calibrated with angiotensin I (MH ϩ ϭ 1296.69) and adrenocorticotropic hormone fragments (1-17, MH ϩ ϭ 2093.09; 18 -39, MH ϩ ϭ 2465.20; 7-38, MH ϩ ϭ 3657.93). For interpretation of the mass spectra, a list of predicted molecular masses was generated by theoretical cleavage with specific endoproteinases using the MS-Digest program (prospector.ucsf.edu). Each peptide was assumed to contain at least one phosphate group. The masses of the peaks recorded in the mass spectra were matched to the calculated masses with an accuracy of ϳ0.1% or better.
Electrospray Mass Spectrometry-For samples infused into an electrospray mass spectometer, the zip tip containing bound phosphopeptides from ephrin-B1 was pre-equilibrated appropriately, washed in 5% formic acid, and eluted in 50% methanol, 5% formic acid directly into a nanospray capillary. Electrospray mass spectra were recorded at a nl/min flow rate on an API 3000 triple quadrupole mass spectrometer in positive ion mode. Q1 scans were acquired with a mass step of 0.1 atomic mass units and a dwell time of 1 ms. For product ion scans of selected doubly charged phosphopeptides, nitrogen was used as the collision gas, and a mass step of 0.2 atomic mass units and a dwell time of 2 ms were used. The collision energy for product ion scans was adjusted individually for each experiment. Ion series in tandem mass spectra were identified with the assistance of the MS-Product program (prospector.ucsf.edu) and BioMultiView (PE-Sciex).
RESULTS

Tyrosine Phosphorylation Sites of Ephrin-B1 Expressed in 293
Cells-To identify which of the six tyrosines in the cytoplasmic domain of ephrin-B1 become phosphorylated upon engagement with EphB receptors, we transfected ephrin-B1 in 293 cells. The transfected cells were stimulated with crosslinked EphB2 Fc, a soluble fusion protein consisting of the ectodomain of EphB2 fused to the Fc portion of human IgG1 and preincubated with anti-Fc antibodies. EphB2 Fc increased the level of ephrin-B1 tyrosine phosphorylation (Fig. 1A) , as expected (12) . For MALDI mass spectrometric analysis, ephrin-B1 immunoprecipitated from EphB2 Fc-treated cells was digested with trypsin and endoproteinase Glu-C. The ephrin-B1 tyrosine-phosphorylated peptides were isolated from the mixture of digested peptides using anti-phosphotyrosine antibodies conjugated to agarose beads. This level of purification, which permits ionization of peptides directly from beads, had previously been sufficient to identify by mass spectrometry the tyrosine-phosphorylated peptides generated from EphB2 and EphB5 expressed in transfected 293 cells (19) . However, additional acidic elution and reverse phase purification steps with microcolumns were required for ephrin-B1 to reduce background noise associated with the previous protocol and detect clearly the lower level of phosphorylation of ephrin-B1.
The resulting improved mass spectra contained only three major peaks corresponding to three ephrin-B1 monophosphorylated peptides: two containing tyrosines 312 and 317 and another containing the carboxyl-terminal tyrosines 331 and 332 ( Fig. 1B and Table I ). This result indicates that one or both of the tyrosines in each peptide are sites of phosphorylation. Unfortunately, it was not possible to more precisely identify the tyrosine phosphorylation sites of ephrin-B1 using this mass spectrometric approach because shorter peptides containing only one of these tyrosines could not be readily obtained with the sequence-specific proteases available.
To directly identify the phosphorylated tyrosines, electrospray tandem mass spectrometry was used to sequence the doubly charged ion of the carboxyl-terminal peptide with a molecular weight of 1488.90 (m/z ϭ 744.8), which contains tyrosines 331 and 332 (Fig. 2) . Upon fragmentation, a series of expected daughter "a," "b," and "y" ions were detected in the spectra, allowing the sequence to be determined from the mass differences between the fragment ions. Most of the sequence was verified by a set of singly and doubly charged carboxylterminal y ions, where the mass difference between y 3 and y 2 indicates phosphorylation at tyrosine 331. Phosphorylation at tyrosine 332, however, was not detected in the y ion series, because the mass difference between y 2 and y 1 only indicates the presence of tyrosine and not phosphotyrosine. As expected, all larger carboxyl-terminal peptides (y 5 -y 11 ), which contain both tyrosines, were detected as monophosphorylated ions. In addition, the amino-terminal b 10 fragment, containing tyrosine 331 but not tyrosine 332, was detected as a monophosphorylated ion. Based on this analysis, tyrosine 331 is the phosphorylation site in the ephrin-B1 peptide with a weight of 1488.90. Because the size of a peak in a MALDI spectrum is not an accurate indication of the abundance of the corresponding peptide, we used site-directed mutagenesis to determine whether FIG. 1. Binding of EphB2 to ephrin-B1 causes phosphorylation of ephrin-B1 on several cytoplasmic tyrosines. a, cross-linked EphB2 Fc up-regulates tyrosine phosphorylation of ephrin-B1 in transfected 293 cells. Extracts from cells that were either transfected with ephrin-B1 cDNA (ϩ) or pcDNA3 control vector (Ϫ) were treated with EphB2 Fc (ϩ) or left untreated (Ϫ). The ephrin-B1 immunoprecipitates were probed with anti-phosphotyrosine antibodies (anti-pTyr) and reprobed with anti-ephrin-B1 antibodies. b, MALDI mass spectrum of tyrosine-phosphorylated peptides from transfected ephrin-B1. Ephrin-B1 was immunoprecipitated from EphB2-Fc-treated cells and digested with trypsin and endoproteinase Glu-C. Tyrosine-phosphorylated peptides were isolated from the resulting peptide mixture by binding to anti-phosphotyrosine antibodies conjugated to agarose followed by purification by reverse phase chromatography, and analyzed by MALDI mass spectrometry in the reflector mode. Peaks corresponding to tyrosine-phosphorylated peptides of ephrin-B1 are denoted by their masses and sequences and are also identified in Table I . P, phosphate group.
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tyrosine 331 is highly phosphorylated. Tyrosine phosphorylation of an ephrin-B1 mutant with phenylalanine at position 331 (ephrin-B1 Y331F) was greatly reduced compared with wild type ephrin-B1 (Fig. 3) . This indicates that tyrosine 331 is a major phosphorylation site of ephrin-B1 in 293 cells stimulated with EphB2 Fc.
To determine whether tyrosine 312 and 317 are phosphorylated, we mutated these tyrosines to phenylalanine. Mutation of either tyrosine slightly reduced tyrosine phosphorylation of wild type ephrin-B1 and the Y331F mutant in 293 cells stimulated with EphB2 Fc (Fig. 3) . This indicates that both tyrosines are phosphorylated but to a lesser degree than tyrosine 331. Thus, the ephrin-B1 peaks detected at 1643 m/z and 1771 m/z (Fig. 1B) likely represent mixtures of two peptides, one phosphorylated at tyrosine 312 and the other phosphorylated at tyrosine 317. This may explain the unclear results obtained with these peptides in tandem mass spectrometry experiments (data not shown).
In the 293 cells, phosphorylation was essentially undetectable for the ephrin-B1 Y312F/Y317F/Y331F mutant, which lacks all three tyrosines (Fig. 3) . Only very long exposures of the film revealed a faint band (data not shown). This suggests that the other three tyrosines present in the cytoplasmic domain of ephrin-B1 are not significantly phosphorylated when ephrin-B1 is stimulated with EphB2 Fc in 293 cells. This conclusion is consistent with the data obtained by mass spectrometry. Fragmentation of the carboxyl-terminal monophosphorylated peptide did not show any evidence of phosphorylation at tyrosine 332 in the tandem mass spectra (Fig. 2) . Furthermore, in the MALDI mass spectra (Fig. 1B) we did not detect peaks corresponding to a doubly phosphorylated peptide containing tyrosines 331 and 332, nor peaks corresponding to phosphorylated peptides containing tyrosines 301 and 305. In addition, mutation of tyrosine 301 and 305 did not detectably reduce the level of ephrin-B1 tyrosine phosphorylation (Fig. 3) .
Ephrin-B1 and EphB2 Are Phosphorylated on Tyrosine in Embryonic Neural Retina-We have previously shown that the EphB2 receptor is phosphorylated on tyrosine in vivo in the developing chicken neural retina (26) . This phosphorylation is presumably caused by ephrin-B ligands that bind to EphB2, causing its activation. Indeed ephrin-B1 and ephrin-B2, two ligands for EphB2, are expressed in the embryonic neural retina (Fig. 4A) (20, 24) . According to the reverse signaling model, ephrin-B ligands in the retina should be phosphorylated on tyrosine upon interaction with EphB2. Consistent with this possibility, we detected ephrin-B1 tyrosine phosphorylation in embryonic retina (Fig. 4B) . The apparent molecular weight of tyrosine-phosphorylated ephrin-B1 is different at different developmental stages, consistent with the presence of several immunoreactive ephrin-B1 bands that are developmentally regulated (Fig. 4A) . The different bands may represent alternatively spliced forms of ephrin-B1, represent proteolytic fragments, or be the result of post-translational modifications. They do not represent other ephrin-B ligands because the antibodies are highly specific for chicken ephrin-B1 and do not cross-react with other ephrin-B ligands. onic retina is intriguing because these proteins have complementary patterns of expression; ephrin-B1 is most highly expressed in the dorsal retina, and EphB2 is most highly expressed in the ventral retina (Fig. 5, A and B) (20, 24, 25) . However, we found that ephrin-B1 is also expressed at low levels in the ventral retina and that EphB2 is also expressed in the dorsal retina (Fig. 5B) . Thus, receptor and ligand show partially overlapping expression and therefore can interact and cause reciprocal tyrosine phosphorylation (Fig. 5, C and D) . Consistent with these patterns of expression, a larger fraction of the ephrin-B1 molecules is tyrosine-phosphorylated in the ventral retina, where EphB2 receptor expression is high (Fig.  5C ). Conversely, a larger fraction of the EphB2 molecules is tyrosine-phosphorylated in the dorsal E12 retina, where ephrin-B1 ligand expression is high (Fig. 5C) . Relatively low levels of EphB2 tyrosine phosphorylation were detected in the E8 retina, as was described previously (26) .
Tyrosine Phosphorylation Sites of Ephrin-B1 in Neural Retina-To identify the tyrosines of ephrin-B1 that are physiologically phosphorylated in vivo in retinal tissue, ephrin-B1 was immunoprecipitated from E12 retina. Following cleavage with proteases, tyrosine-phosphorylated peptides were isolated for MALDI mass spectrometry. The profile of ephrin-B1 tyrosinephosphorylated peptides from retina was remarkably similar to that from 293 cells. The same three major peaks were obtained ( Fig. 6 and Table I), although the relative heights of the peaks were different. In ephrin-B1 from retina, the 1643 and 1771 m/z peaks (both of which contain tyrosines 312 and 317) were more prominent that the 1488 m/z peak (which contains tyrosine 331). In contrast, the 1488 m/z peak was more prominent in the ephrin-B1 sample from 293 cells. This may reflect dif-FIG. 5. EphB2 and ephrin-B1 have partially overlapping distributions and are substantially phosphorylated on tyrosine in the developing chicken retina. A, immunoperoxidase labeling (dark) shows that EphB2 protein is concentrated in the ventral retina, whereas ephrin-B1 protein is concentrated in the embryonic dorsal retina. Paraffin sections cut vertically from the same region of an E6 chicken head were stained with antibodies to ephrin-B1 and EphB2. The arrows mark the position of the optic fissure (of), located in the middle of the ventral retina. B, immunoblotting shows that ephrin-B1 is also expressed in the ventral retina, although at a low level, and EphB2 is also expressed in the dorsal retina, although at a low level. Retinas were cut in four parts, perpendicular to the optic fissure. Dt, top half of the dorsal retina; Db, bottom half of the dorsal retina; Vt, top half of the ventral retina; Vb, bottom half of the ventral retina. The left panel is an Amido Black-stained filter, which shows that equal amounts of protein were present in the lanes. In the right panel, the top portion of the same filter was probed with antibodies to EphB2, and the bottom portion was probed with antibodies to ephrin-B1. C, EphB2 and ephrin-B1 are both phosphorylated on tyrosine in the dorsal and the ventral retina. Ephrin-B1 and EphB2 were immunoprecipitated (IP) from dorsal (D) and ventral (V) retina and probed by immunoblotting with anti-phosphotyrosine (PTyr) antibodies followed by anti-ephrin-B1 or anti-EphB2 antibodies, respectively. Note that the phosphotyrosine signal for EphB2 is higher in E12 dorsal that ventral retina even though less EphB2 was immunoprecipitated. In contrast, the phosphotyrosine signal for ephrin-B1 is higher in ventral than dorsal retina, even though less ephrin-B1 was immunoprecipitated. D, EphB2 and ephrin-B1 are both phosphorylated on tyrosine in the top half of the dorsal retina and the bottom half of the ventral retina. This experiment was carried out as in C but using only the halves of the dorsal or ventral retina that are distal from the dorsal-ventral midline. Phosphorylation in these regions confirms that the interaction between EphB2 and ephrin-B1 is not restricted to the border of their expression domains in the region between dorsal and ventral retina. IB, immunoblot. ferences in the extent of ephrin-B1 phosphorylation at different tyrosines in the retina and 293 cells. Alternatively the samples may have been digested differently by the proteases, or there may have been different components in the retina and the 293 cell samples, which differentially affected the amount of each peptide that was ionized. An additional peak of 1851 m/z was also observed in the ephrin-B1 sample from retina, which corresponds to a peptide containing tyrosines 312 and 317 and two phosphates. In this peptide, both tyrosines may be phosphorylated, or serine 309 may be phosphorylated in addition to one of the tyrosines.
Tyrosine Phosphorylation Sites of EphB2 in Neural Retina and 293 Cells-We used the same MALDI mass spectrometry approach to identify EphB2 tyrosine-phosphorylated peptides in retinal tissue. Many peaks were present in the spectra of EphB2 immunoprecipitated from E12 retina and digested with trypsin and endoproteinase Glu-C, and most of the major peaks have masses corresponding to EphB2-phosphorylated peptides ( Fig. 7A and Table II ). These peptides contain many of the same tyrosines previously identified as phosphorylation sites of EphB2 expressed in 293 cells (19) . Thus, many tyrosines in the cytoplasmic domain of EphB2 appear to be phosphorylated in retina tissue as they are in the 293 cells. In particular, four prominent peaks from retinal EphB2 correspond to peptides containing the juxtamembrane tyrosines 605 and 611. Differences were noted, however, in the relative representation of peptides containing different tyrosines. In the spectra of EphB2 from retina, for example, three of the twelve EphB2 peaks correspond to peptides containing tyrosine 668, whereas peptides containing this tyrosine had been poorly represented in spectra of EphB2 from 293 cells (19) . In addition, one of the peaks corresponds to a peptide that contains tyrosines 821 and 831, two residues that had not been previously identified as phosphorylation sites.
To determine whether these differences were caused by the modifications introduced in the protocols used, we obtained a MALDI mass spectrum of phosphopeptides from EphB2 overexpressed in 293 cells using the same protocol used for retinal EphB2 (Fig. 7B and Table II) . Modifications of the previous protocol involve isolating EphB2 by immunoprecipitation (rather than using immobilized ephrin-B1 Fc or glutathione S-transferase fusion proteins of SH2 domains) (19) and eluting the peptides from the anti-phosphotyrosine antibody coupled to beads followed by a reverse phase chromatographic step. These modifications improve sensitivity and selectivity, because they reduce the number of background peaks that do not correspond to EphB2 phosphopeptides. This analysis identified an additional tyrosine (tyrosine 821) of EphB2 from 293 cells as a FIG. 6 . In vivo tyrosine phosphorylation sites of ephrin-B1 in E12 retina. MALDI mass spectrum of tyrosine-phosphorylated peptides from ephrin-B1 immunoprecipitated from retina tissue and digested with trypsin and endoproteinase Glu-C. Tyrosine-phosphorylated peptides were isolated from the resulting peptide mixture by binding to anti-phosphotyrosine antibodies conjugated to agarose followed by purification by reverse phase chromatography. Peaks corresponding to tyrosine-phosphorylated peptides of ephrin-B1 are denoted by their masses and sequences and are also identified in Table I .
FIG. 7.
In vivo tyrosine phosphorylation sites of EphB2 from E12 retina and transfected 293 cells. MALDI mass spectra of tyrosine-phosphorylated peptides from EphB2 immunoprecipitated from retina tissue (A) or transfected 293 cells (B) and digested with trypsin and endoproteinase Glu-C. Tyrosine-phosphorylated peptides were isolated from the resulting peptide mixture by binding to anti-phosphotyrosine antibodies conjugated to agarose followed by purification by reverse phase chromatography. Peaks corresponding to tyrosine-phosphorylated peptides of EphB2 are denoted by their masses and identified in Table II . The tyrosine residues contained in each peptide are also indicated in boxes.
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phosphorylation site, consistent with the identification of peptides containing this tyrosine in the EphB2 retinal sample. Thus, tyrosine 821 is one of the in vivo phosphorylation sites of EphB2. In addition, peptides containing tyrosines 605, 611, 668, 789, and 939 were detected in EphB2 from both retina and 293 cells, consistent with previous results (19) . In the 293 cell sample, all five most prominent peaks correspond to peptides containing tyrosines 605 and 611. Hence, many in vivo tyrosine phosphorylation sites are similar in EphB2 ectopically expressed in 293 cells or endogenously expressed in embryonic retinal tissue.
Interestingly, the majority of the EphB2 phosphopeptides obtained from retina and 293 cells were different, even though they contained the same tyrosines. This suggests differential protease digestion and/or differential detection of EphB2 peptides from retina and 293 cell samples. These factors may also explain some of the discrepancies in the phosphorylation sites identified in 293 cells and retina. Peptides containing tyrosines 745, 751, and 921 were detected in EphB2 from 293 cells and not retina, whereas peptides containing tyrosine 586 were detected only in retina (although tyrosine 586 had been previously identified as a phosphorylation site of EphB2 in 293 cells (19) ). The differences observed in the spectra may also reflect some differences in the phosphorylation sites of EphB2 in embryonic retina and 293 cells. Further experiments digesting EphB2 with different combinations of proteases may help resolve these issues.
DISCUSSION
Ephrin-B1 and EphB2 Tyrosine Phosphorylation in Embryonic Retina-We previously reported that the EphB2 receptor is substantially phosphorylated on tyrosine in the developing neural retina (26) . This finding suggested that ligands that stimulate EphB2 phosphorylation must also be expressed in this tissue. Indeed, ephrin-B1 and ephrin-B2 are expressed in the embryonic retina (20, 24) . Consistent with binding of ephrin-B1 to EphB2 in the retina, we show here that not only EphB2 but also ephrin-B1 is phosphorylated on tyrosine in retinal tissue.
At E8 and E12, ephrin-B1 is more highly expressed in the dorsal half of the chicken retina, and EphB2 is more highly expressed in the ventral half (20, 24) . Interaction and tyrosine phosphorylation of ephrin-B1 and EphB2 could occur at the boundary between their regions of expression. In the hindbrain, for example, Eph receptors and ephrins are present in adjacent rhombomeres, and their activation at the boundaries prevents intermingling of cells between rhomobomeres (7, 8) . However, our data indicate that phosphorylation is not restricted to the boundary between dorsal and ventral retina. Tyrosine-phosphorylated EphB2 and ephrin-B1 were detected not only in the central portions of the retina but also in the distal dorsal and ventral portions. This is consistent with their overlapping expression in the top half of the dorsal retina (where ephrin-B1 expression is high and EphB2 expression is low) and the bottom half of the ventral retina (where EphB2 expression is high and ephrin-B1 expression is low). Interestingly, at earlier developmental stages EphB2 and ephrin-B1 overlap even more extensively, at least in the mouse retina (13) . Additional EphB receptors and ephrins expressed in the retina (28) likely also contribute to the spatial patterns of ephrin-B1 and EphB2 tyrosine phosphorylation. For example, the presence of another EphB receptor competing with EphB2 for binding to ephrin-B1 in the E8 retina could explain the low 
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levels of EphB2 phosphorylation observed at this stage. In addition, growth factor receptor tyrosine kinases may also cause phosphorylation of ephrin-B1 in the retina (10, 12, 29) . Notably, fibroblast growth factor can up-regulate tyrosine phosphorylation of endogenous ephrin-B1 in embryonic retinal tissue (10) . Ephrin-B1 Phosphorylation Sites-Various stimuli can induce tyrosine phosphorylation of ephrin-B1, including binding to EphB receptors, activation of Src kinase, platelet-derived growth factor stimulation and, as mentioned above, fibroblast growth factor stimulation (10, 12, 18) . The Tie-2 receptor and fibroblast growth factor receptor 1 can also phosphorylate the cytoplasmic domain of ephrin-B1 in vitro (10, 29) . Ephrin-B1 is tyrosine-phosphorylated in mouse embryonic tissues (18) and, as we show here, in chick embryonic retina. The precise physiological consequences of ephrin-B1 phosphorylation, however, remain to be determined. One report shows that tyrosine phosphorylation of the cytoplasmic domain of ephrin-B1 inhibits its ability to cause cell dissociation in Xenopus embryos (10) . In addition, EphB-dependent activation of ephrin-B signaling has been implicated in pathfinding of anterior commissure axons (30) and dorsal retinal ganglion cell axons (13) . The molecular mechanisms involved in pathfinding of ephrin-B1-bearing axons remain to be determined, but presumably ephrin-B1 tyrosine phosphorylation plays a crucial role.
We have developed approaches that for the first time identify the in vivo tyrosine phosphorylation sites of ephrin-B1. By MALDI mass spectrometry, we have detected the same tyrosine-phosphorylated peptides containing tyrosines 312/317 and 331/332 in both embryonic retinal tissue and 293 cells stimulated with multimeric EphB2 Fc. If phosphorylation of ephrin-B1 is influenced by its oligomeric state or the nature of the stimulus (interaction with EphB receptors or activation of other receptor tyrosine kinases), then the transfected 293 cells closely mimic the in vivo situation in neural tissue. Electrospray tandem mass spectrometry and site-directed mutagenesis more precisely identified tyrosines 312, 317, and 331 of ephrin-B1 as phosphorylation sites. These sites are likely to have physiological significance because they are present in vivo.
We have determined that tyrosine 331 is the major in vivo phosphorylation site of ephrin-B1 bound to EphB2. Tyrosine 331 is the residue at the Ϫ3 position from the carboxyl terminus of ephrin-B1 and part of the PZD domain-binding site. Several PDZ domain-containing proteins bind to ephrin-B1. They include GRIP1, GRIP2, and syntenin, which are adaptor proteins that consist solely of PDZ domains; the protein kinase C-interacting protein Pick1, the phosphotyrosine phosphatase FAP-1; PHIP, which is related to a Caenorhabditis elegans protein involved in regulating polarity in the early embryo; and PDZ-RGS3, which functionally connects B-ephrins and trimeric G proteins (17, (31) (32) (33) . Interaction of ephrin-B1 with these PDZ proteins may contribute to the localization and clustering of ephrin-B1 and mediate downstream signaling events. Structural studies have suggested that the residue at the Ϫ3 position confers binding specificity for the PDZ domain (34) . Thus, phosphorylation at tyrosine 331 could differentially affect the affinity of ephrin-B1 for different PDZ domains. Ephrin-B1 phosphorylation, however, has not been found to drastically affect most PDZ domain interactions examined so far (33) .
The residue at position Ϫ2 from the carboxyl terminus is also important for regulating PDZ domain binding (35) and is also a tyrosine in ephrin-B1 (tyrosine 332). Phosphorylation at the Ϫ2 position affects binding of an ephrin-B1 synthetic peptide to syntenin (33) . However, we have found no evidence that tyrosine 332 is phosphorylated. MALDI mass spectra identified only the monophosphorylated form of the peptide containing tyrosines 331 and 332, and electrospray mass spectra only detected tyrosine 331 as a phosphorylated amino acid in this peptide. Consistent with the mass spectrometry data, an ephrin-B1 mutant containing tyrosine 332, but not tyrosines 312, 317, and 331, was not significantly phosphorylated in 293 cells treated with EphB2 Fc.
Motifs of ephrin-B1 containing phosphorylated tyrosines could represent binding sites for Src homology 2 (SH2) domains or phosphotyrosine-binding domains. Interestingly, the ephrin-B1 interacting proteins identified so far contain PDZ domains and not SH2 or phosphotyrosine-binding domains. Indeed, pull-down assays could not detect interactions between tyrosine-phosphorylated ephrin-B1 and a number of known SH2 domains fused to glutathione S-transferase, including those of Src, Abl, Arg, phosphatidylinositol 3-kinase, SHEP1, RasGAP, Crk, Grb10, and ShcB.
2 Additional experiments will determine whether other SH2 or phosphotyrosine-binding domains could bind to phosphorylated ephrin-B1 and mediate ephrin-B1 signals. Unfortunately, the sequences near tyrosines 312, 317, and 331 do not provide strong clues as to which other SH2 domains should be examined (36, 37) . On the other hand, tyrosines 312 and 317 have been shown to be required for association with activated fibroblast growth factor receptor 1 (10) .
The identity of the kinase(s) that phosphorylate the B-ephrins remains a mystery. Interestingly, however, tyrosine 317 and 331 are in sequence contexts that may be preferentially phosphorylated by a receptor tyrosine kinase (38) . In contrast, a cytoplasmic tyrosine kinase such as Abl is more likely to phosphorylate tyrosine 312. Perhaps, different tyrosine kinases phosphorylate different tyrosines of ephrin-B1.
EphB2 Phosphorylation Sites-We have also identified the tyrosine residues of EphB2 that are phosphorylated in vivo in retinal tissue. Many of the tyrosines in the EphB2 cytoplasmic domain are phosphorylated in the E12 retina. The multiple phosphorylation sites detected in 293 cells (39) (Fig. 7B) , therefore, are not artifacts caused by overexpression of transfected EphB2. The juxtamembrane tyrosines 605 and 611, in particular, appear to be prominent phosphorylation sites in both retinal tissue and cultured cells. Phosphorylation of these tyrosines regulates both binding of many SH2 domain-containing proteins and kinase activity (39, 40) . Thus, tyrosines 605 and 611 could play a particularly important functional role in EphB2 signaling in vivo. Phosphorylation of tyrosine 779, the conserved tyrosine in the activation loop of the kinase domain, likely also regulates kinase activity. Other phosphorylation sites were identified within the kinase domain, including tyrosines 668, 741/751, and 821. Phosphorylation of these tyrosines may also affect EphB2 kinase activity as well as represent protein-binding sites that are regulated by phosphorylation. Although mass spectrometry does not provide precise quantitative information, tyrosine 668 in the kinase domain was represented by several large peaks in the spectra from retinal tissue. This may imply that this tyrosine is a prominent phosphorylation site in the retina. Interestingly, tyrosine 668 in the kinase domain and tyrosine 586 in the juxtamembrane domain are predicted to have similar binding specificity for SH2 domains because both are in a similar sequence context ( 586 YTDK and 668 YTEK) (36, 37) . Experiments are in progress to determine whether tyrosines 586 and 668 mediate the phosphorylation-dependent protein interactions that do not depend on tyrosines 605 and 611 of EphB2 (40, 41) . Whether the identified phosphorylation sites of EphB2 are the result of autophosphorylation or are phosphorylated by other tyrosine kinases remains to be
determined, but they are likely to be physiologically relevant because they are phosphorylated in vivo in neural tissue.
Identification of tyrosine phosphorylation sites is an important step in understanding tyrosine kinase signaling pathways. As more sensitive methods are used, it becomes increasingly clear that many tyrosines in proteins have the potential to be phosphorylated. Thus, regulation of proteins by tyrosine phosphorylation may be a much more prevalent form of regulation than previously thought. Some of the phosphorylation sites may occur with low stoichiometry or be phosphorylated only very transiently. Nevertheless, these phosphorylation sites could have important functions. Mass spectrometry has made possible the identification of in vivo phosphorylation sites in live cells grown under physiological phosphate concentrations and in tissues (19, 27, 42, 43) . We have identified the tyrosine phosphorylation sites of ephrin-B1 and EphB2 in a tissue where these proteins are normally expressed and tyrosinephosphorylated. Identification of the sites that are phosphorylated in tissues will help elucidate the physiological mechanisms underlying the activities of ephrin-B ligands and EphB receptors. For example, it will be possible to genetically engineer mice expressing tyrosine mutants of ephrin-B1 and EphB2 to identify the in vivo function of each phosphorylation site. Antibodies specific for each phosphorylation site may also yield important insights as to the spatial distribution of the tyrosine-phosphorylated forms of these proteins, which are the forms activated to signal.
